We sought to investigate whether drug-induced changes in contractility were affected by pacing rates that represent the range of heart rates encountered in vivo. Using the cell geometry measurement system (IonOptix), we paced dog cardiomyocytes at different cycle lengths (CLs) of 2000, 1000, 500, and 333.3 ms, before and after exposure to 13 inotropic drugs. Time course data using vehicle control (0.1% dimethyl sulfoxide (DMSO)) demonstrated stability of the system at all CLs tested. Seven positive inotropes (eg isoproterenol) exerted rate-dependent increases in sarcomere shortening ( hysteresis loop, although rate dependency was seen with verapamil only. Positive inotropes (eg isoproterenol and levosimendan) induced a rate-dependent increase in the area, however Omecamtiv mecarbil increased and decreased the area at CLs of 2000 and 333.3 ms, respectively. Thus, the use of different pacing rates may improve the detection of inotropes in early drug discovery and illustrate the potential for finger-printing different mechanisms of action.
INTRODUCTION
Progression of new therapies to patients can be limited by an unacceptable cardiac safety profile, which is one of the major reasons for drug attrition and withdrawal from sale (Cook et al., 2014; Kola and Landis, 2004; Munos, 2009; Redfern et al., 2003) . This concern has led to the adoption of cardiac safety assessment strategies which aim to assess the cardiotoxic potential of new drugs before they enter clinical trials (Harmer et al., 2012; Pollard et al., 2010) . This is particularly true for unintended side effects of drugs that affect myocardial force of contraction (cardiac inotropy), which represents the intrinsic ability of the heart to contract. For example, recent data have implicated smallmolecule kinase inhibitors and antibody-based cancer therapies in adversely affecting myocardial contractility and decreasing left ventricular ejection fraction (Force et al., 2007; Mellor et al., 2011) . Although it is not a requirement of the preclinical safety guidelines to assess myocardial contractility prior to dosing a new drug for the first time into humans (Anonymous, 2000) , evaluation of the effects of new drugs on cardiac inotropy is regarded as an essential assessment in the pharmaceutical industry to determine the suitability of a candidate drug to continue on a development path.
Detailed preclinical assessment of cardiac inotropy typically involves in vivo studies or isolated whole heart models (Cambridge and Whiting, 1986; Guo et al., 2009; Klumpp et al., 2006; Markert et al., 2007) , although such studies are limited in throughput. In order to detect and eliminate potential inotropic liability early in a drug discovery program, there has been a shift in emphasis with respect to developing new in vitro models with higher throughput. Freshly isolated cardiomyocytes are capable of identifying the inotropic liability of drugs (Harmer et al., 2012) . Moreover, stem cell-derived cardiomyocytes are also capable of classifying drugs as cardiotoxic or cardiosafe, when relying on the beating as a biomarker to predict the risk that a drug may affect inotropy (Hayakawa et al., 2014; Himmel, 2013; Pointon et al., 2014; Scott et al., 2014; Sirenko et al., 2013a, b) . Although a wide array of methods (cellular impedance, Ca 2þ transients, mechanical movement, image-based contractile motion, and video-based cell geometry system to measure sarcomere dynamics) is utilized for screening effects of drugs on cardiomyocyte contraction, data were obtained in either cells paced at one cycle length (CL; Harmer et al., 2012) or spontaneously beating stem cell-derived cardiomyocytes (Hayakawa et al., 2014; Himmel, 2013; Huebsch et al., forthcoming; Peters et al., 2015; Scott et al., 2013) . Despite that they are not limited by assay throughput, these new in vitro cardiac models offer no insight into the mechanisms of drug-induced changes in cardiomyocyte contraction (Harmer et al., 2012; Pointon et al., 2014) . In order to detect and eliminate potential inotropic liability early in drug discovery, a contractility assay to better characterize inotropes and provide mechanistic insights would be highly valuable. Harmer et al. (2012) developed an in vitro contractility assay, which measures sarcomere shortening (Sarc. short.) in single cardiomyocytes that are stimulated to contract at a CL of 1000 ms (ie 1 Hz pacing frequency). We have therefore sought to extend the assay reported by Harmer et al. (2012) by measuring contractility parameters and hysteresis loops of Ca 2þ transients versus Sarc. short. in isolated canine cardiomyocytes at different CLs that represent the range of heart rates encountered in vivo. Our findings support the concept that the use of different CLs and hysteresis loops generates an enhanced dataset, better characterizes inotropes, illustrates the potential for finger-printing different mechanistic insights, which could include those involving ion channels, enzymes, Ca 2þ handling and contractile proteins, and increases the usefulness of cardiac inotropy assessment in early drug discovery.
MATERIALS AND METHODS
Isolation of cardiomyocytes. Female beagle dogs (weight 9.7-13.7 kg; age 17-60 months) were used and maintained in accordance with the Guide for The UK Home Office Code and Practice for the Housing and Care of Animals used in Scientific Procedures. The procedures were authorized under a project licence granted under the Animals (Scientific Procedures) Act 1986. Cardiomyocytes were isolated enzymatically from the left ventricular midmyocardium of the heart as previously described Johnson et al., 2011 Cardiomyocyte contractility measurement. Sarc. short. was recorded from cardiomyocytes at physiological temperature as previously described (Harmer et al., 2012) . Briefly, contractile properties of myocytes were assessed using a video-based cell geometry system to measure sarcomere dynamics (IonOptix, Dublin, Ireland; Ren and Wold, 2001 ). Myocytes were placed in a perfusion chamber (FHC Inc., Bowdoinham, ME) mounted on the stage of an inverted Nikon TE200 microscope (Nikon UK, Surrey, UK). The microscope stage (Prior Scientific Instruments, Cambridge, UK) was motorized and controlled remotely. Myocytes were continuously perfused from a gravity fed system at 2 ml/min with standard myocyte Tyrode solution heated to approximately 36 C using a line heater (Cell MicroControls, Norfolk, VA). The myocytes were field stimulated with suprathreshold voltage at different CLs, with a bipolar pulse of 3 ms duration, using a pair of platinum wires placed on opposite sides of the chamber connected to a MyoPacer EP stimulator (IonOptix).
Myocytes were imaged at 240 Hz using an IonOptix Myocam-S CCD camera. Digitized images were displayed within the IonWizard acquisition software (IonOptix). The longitudinal axis of the myocyte of interest was aligned horizontally, parallel to the video raster line, by means of a semiautomated dovecote prism optical system that could be controlled remotely (Cairn Research, Faversham, UK) . Optical intensity data were collected from a user-defined rectangular region of interest placed over the myocyte image. The optical intensity data represent the bright and dark bands corresponding to the Z-lines of the cardiomyocyte. The IonWizard software analyzes the periodicity in the optical density along the myocyte due to these bands by means of a fast Fourier transform algorithm. Study design. Each experiment typically measured drug responses from 9 myocytes taken from a single dog heart. After myocytes were added to the microscope stage, they were allowed to settle for approximately 2 min. After this, perfusion with the standard myocyte Tyrode solution (with 0.1% DMSO as the vehicle control) was started. At this time, cells were also field stimulated at a CL of 1000 ms (ie 1 Hz pacing frequency) and left to acclimatize for a further 2 min at approximately 36 C. Prior to the start of each experiment, individual myocytes were selected at a CL of 333.3 ms (ie pacing frequency of 3 Hz): Myocytes were not selected if three contractions were not captured per second. Myocytes with obvious sarcolemmal blebs or spontaneous contractions were not used for recording. If a myocyte was deemed suitable for recording, then its position was recorded using the motorized stage controller. Once the positions for myocytes (we aimed to select 9 cells, although this number might have been less on some occasions) were collected, then the experiment was started. Initially, rate adaptation in the presence of the vehicle control was investigated by changing the CL in the following sequence: 2000, 1000, 500, and 333.3 ms (0.5, 1, 2, and 3 Hz, respectively) while ensuring steady state was achieved at each CL prior to changing to the next rate. One concentration of the test item was applied at 2000 ms CL while viewing the final cell in the sequence after the original CL sequence. Following exposure at 2000 ms CL, the sequence 1000, 500, and 333.3 ms was repeated while data continued to be captured for each CL.
Once the sequence was completed, contractility data in the presence of the test item for the other cardiomyocytes were also captured. During this period, the magnitude of the myocyte contractions could be monitored on-line, such that a judgment could be reached whether a steady-state effect has been achieved (ie if a stable decrease or increase in Sarc. short. had occurred). For all of the drugs that were active, a steady state was achieved within 250 s. Although the same experimental design was repeated while recording Sarc. short. and Ca 2þ transient simultaneously, only one cell was selected for both recordings.
Data quantification and statistical analysis. Initial analysis was performed using the IonWizard software. For each test condition, data for 10-15 contractions were averaged, using the pacing time as common reference point, to give a single representative monotonic contractility transient. A series of polynomials were fitted to the 5 different phases of the monotonic transient. From this analysis, fractional Sarc. short., which indicates the percentage of peak contraction relative to the resting length, was used to quantify sarcomere dynamics (Fig. 1A ). Data were normalized to the first application of the vehicle control and noncumulative concentration-effect (C-E) curves were constructed for each drug. Where a negative inotropic effect was observed with a drug, the data were then fitted to a simple block model using a custom-written Origin 7.5 (OriginLab Corporation)-based fitting program to determine IC 50 (molar concentration producing 50% inhibition), allowing the Hill coefficient to vary but assuming that the drug would eventually cause complete inhibition of the contractility. For positive inotropes, it was often difficult to quantify the effects at the top of the C-E curve, as these drugs often cause the cardiomyocytes to "fibrillate. Results are expressed as mean 6 SEM. Differences, when investigating the molecular mechanism of Omecamtiv mecarbil (CK-1827452), were tested for statistical significance using a paired t test (2-sided at the 5% significance level) as same cells were used to generate data. Since (1) there were no experimental repeats for any drugs (only technical repeats; so the "occasion to occasion" reproducibility could not be assessed), (2) this study was not powered to detect effects of a particular size as significant, and (3) no aggregation over the drugs was possible as each drug had the potential to respond differently to changes in CL, differences in the rest of the dataset were not tested for statistical significance.
RESULTS
Sarcomere Shortening-CL Relationship and Time Control Data Before constructing C-E curves for the effect of drugs on Sarc. short., we first investigated the Sarc. short.-CL relationship and established time data control for the vehicle. The Sarc. short.-CL relationship was investigated in 766 cardiomyocytes used in this study by measuring Sarc. short. in vehicle conditions with changing CLs from long to short cycles. The rate adaptation was assessed under the same experimental conditions (ie same stimulus settings, heating and vehicle solution) for each run of selected cardiomyocytes (n ¼ 112 runs used in this investigation) and the values generated on each run were technical repeats. An increase (positive relationship) and a decrease (negative relationship) in Sarc. short. were observed in 6 (5%) and 84 (75%) runs, respectively, albeit 22 (20%) runs showed flat relationship. Grouped average data show a negative relationship with a marked effect at a CL of 333.3 ms (medians were 6.9, 7.3, 7.4, and 6.1 at CLs of 2000, 1000, 500, and 333.3 ms, respectively; Fig. 1A ).
Using our study design, the effects of vehicle control used for both the first and second applications were tested. When the first application was normalized to 100%, the second application of vehicle control gave the following changes in Sarc. short. (n ¼ 39): 93.1 6 2.7%, 94.5 6 2.3%, 93.1 6 1.9%, and 95.3 6 2.8% at CLs of 2000, 1000, 500, and 333.3 ms, respectively (Fig. 1B) . Thus, we concluded that our study design was suitable for further pharmacological examination of the assay.
Effects of Inotropes on Sarcomere Shortening in Cardiomyocytes Paced at Different CLs
Having demonstrated that our study design is capable of providing stable recordings of Sarc. short. that can be used to generate meaningful C-E curves, we went on to test a diverse range of drugs that would demonstrate the ability of this study design to detect different pharmacological mechanisms that affect cardiomyocyte contraction. Of the drugs tested, seven and six were positive and negative reference inotropes.
An increase in Sarc. short was observed with adrenergic ago- formed a counter-clockwise loop (Fig. 4A) , as an analogy to the pressure-volume relationship diagrams used to assess contractile performance of the heart. During the relaxation phase, the Sarc. length and Ca 2þ transient converge to a common trajectory. This common trajectory occurs during the Ca 2þ decline at a time point shortly after Sarc. relengthening begins (Fig. 4A) . During b-adrenergic stimulation with 0.1 mM isoproterenol, the hysteresis loop showed alterations in cardiomyocytes paced at a CL of 2000 ms as compared with the loop of cardiomyocytes from vehicle control conditions ( Fig. 4B ; n ¼ 6): an upwards left shift of the relationship (pointing to increased Sarc. short. for any given cytosolic Ca 2þ ), a start of Sarc. short. at lower Ca 2þ and a bigger area of the loop. Although similar alterations were observed at a CL of 333.3 ms, the bigger area of isoproterenolinduced loop at 333.3 ms points toward higher contractile function at short CLs as compared with long CLs (Fig. 4B ; Supplementary Fig. 3A ). During Ca 2þ sensitization with 10 mM levosimendan, a bigger area of the loop was seen at long CLs as compared with the area of the loop of cardiomyocytes from vehicle control conditions; however, a start of Sarc. short. at higher Ca 2þ was seen with no shift of the relationship (Supplementary Fig. 4 ; n ¼ 6). Although similar alterations were seen at short CLs with levosimendan, the bigger area of levosimendan-induced loop at short CLs points toward higher contractile function at these CLs as compared with long CLs ( Supplementary Fig. 4 ). As for isoproterenol and levosimendan, a bigger area of the loop was also seen during activation of cardiac myosin with 1 mM omecamtiv mecarbil at long CLs as compared with the vehicle control loop, but the Sarc. short. started at the same level of Ca 2þ without any shift ( Fig. 4C; Supplementary Fig. 3B ; n ¼ 4). However, in contrast to isoproterenol and levosimendan, a smaller area of the loop was seen with omecamtiv mecarbil at short CLs as compared with vehicle control loop ( Fig. 4C; Supplementary Fig. 3B ). A smaller area of the loop was seen with either inhibition of sodium channel (10 mM flecainide; Fig. 4D ; Supplementary  Fig. 3C ; n ¼ 4) or cardiac myosin ATPase II (30 mM BTS; Fig. 4F ; Supplementary Fig. 3E ; n ¼ 5) at long CLs as compared to vehicle control loop, with the Sarc. short. starting at the same level of Ca 2þ without any shift in the relationship. Although a similar alteration of the loop was also seen with both flecainide and BTS at short CLs with a start of Sarc. short. at lower Ca 2þ , the decrease in the area of the loop was not markedly different between CLs ( Fig. 4D and F; Supplementary Fig. 3C and E). Like flecainide and BTS, although a smaller area of the loop was seen with inhibition of the calcium channel (1 mM verapamil) at all CLs as compared with vehicle control loop, the decrease in the area of the loop was rate dependent with the relationship shifted to the left ( Fig. 4E; Supplementary  Fig. 3D ; n ¼ 6).
Effects of Inotropes on Myofilament
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-Binding Affinity in Cardiomyocytes Paced at Different CLs? Data derived from our study are summarized in Figure 5 . For each drug, Figure 5 lists the known inotropic effect and details the concentration range. It also summarizes the effects of all 13 drugs on the Sarc. short. and describes qualitative alterations in the hysteresis loops upon treatment with 6 drugs. The use of different CLs, when measuring Sarc. short. only, generated an enhanced dataset and uncovered particular C-E curve behaviors (Fig. 5 ) that we described as follows: (1) an "unchanged IC 50 /rate-independent" behavior was seen with 4 negative inotropes (Fig. 3) , (2) "right-and left-shifted IC 50 /rate-dependent" behaviors were observed with BTS ( Fig. 3B) and verapamil (Fig. 3F) , respectively, (3) a "rate-dependent increase in Sarc. short." behavior was seen with 6 positive inotropes (Fig. 2) , and (4) a "rate-dependent atypical" behavior was observed with omecamtiv mecarbil (Fig. 2F) . These particular C-E curve behaviors were not seen when positive (digoxin, epinephrine, FIG. 3 . Potency information generated with negative inotropes from cardiomyocytes paced at different CLs. Typical noncumulative C-E curves generated by the cardiomyocyte contractility measurements with 6 reference negative inotropic drugs (A-F) are shown at CLs of 2000 ( ), 1000 ( ), 500 ( ), and 333.3 ( ) ms. Each plot shows the effect of a test drug on fractional Sarc. short. As well as the mean data points and the fitted C-E curves, each graph also shows the normalized vehicle data next to the y-axis. Full color version available online.
isoproterenol, levosimendan, and milrinone) and negative (flecainide, quinidine, and verapamil) inotropes were tested in the Harmer et al. (2012) contractility assay. Thus, the different CLbased method not only detects a change in Sarc. short. but also may provide an improved ability to detect the inotropes when using shorter CLs and increase the value of the contractility assay in early drug discovery.
As well as the particular C-E curve behaviors, the use of different CLs, when measuring Sarc. short. and Ca 2þ transient simultaneously, also revealed particular hysteresis loop behaviors (Fig. 5 ) that we exemplified as follows: (1) a "downward decrease in the loop/rate independent" behavior was seen with two negative inotropes (flecainide [ Fig. 4D ; Supplementary Fig.  3C ] and BTS [ Fig. 4F ; Supplementary Fig. 3E ]), although (2) a "downward left decrease in the loop/rate dependent" behavior was observed with verapamil ( Fig. 4E; Supplementary Fig. 3D ), another drug with negative inotropic effect, (3) "upward left increase in the loop/rate dependent" and "upward increase in the loop/rate dependent" behaviors were observed with isoproterenol ( Fig. 4B; Supplementary Fig. 3A ) and levosimendan ( Supplementary Fig. 4) , respectively, and (4) a "rate-dependent increase or decrease in the loop" behavior was seen with omecamtiv mecarbil ( Fig. 4C; Supplementary Fig. 3B ). Thus, these particular C-E curve and hysteresis loop behaviors, when assessing the inotropic liability of novel drugs, may illustrate the potential for finger-printing different mechanisms of action that could include those on ion channels, enzymes, Ca 2þ handling and contractile proteins. 
DISCUSSION
The use of phenotypic contractility screening to detect and eliminate potential inotropic liability early in drug discovery is currently being employed, although the ability of this approach to enable inferences to be made about mechanisms of action is limited. Here, we have shown that the assessment of contractility parameters and hysteresis loops in isolated cardiomyocytes at different pacing rates that represent the range of heart rates encountered in vivo can (1) provide an improved ability to detect the inotropes, (2) illustrate the potential for finger-printing different mechanisms of action, and (3) therefore notably increase the value of the contractility assay in early drug discovery. Heart rate regulation of myocardial contractility is critical for cardiac function. This property has been demonstrated in cardiac preparations from different species (like isolated cardiomyocytes, papillary muscles, ventricular trabeculae, left ventricular strips, and isolated hearts). Increasing the pacing rate from slow to fast resulted in an increase in cell shortening in mice (Kushnir et al., 2010; Lim et al., 2000) , rat (Borzak et al., 1991, Coutu and Metzger, 2002; Frampton et al., 1991 , Joulin et al., 2009 , rabbit (Meyer et al., 1999) , and nonfailing human (Brixius et al., 2001 ) cardiomyocytes, whereas a decrease in cell shortening was seen in cat (Wang et al., 2001 ) and rat (Rota et al., 2005) cardiomyocytes. Our data of averaged runs show that 75%, 5%, and 20% of dog cardiomyocytes used in this study exhibited a decrease, an increase and flat response in Sarc. short., respectively, when CL was changed from long to short cycles. The flat response was also seen in a ventricular trabeculae preparation from nonfailing human heart (Chaudhary et al., 2004) . Furthermore, a study in rat cardiomyocytes indicates that the final contractile response observed during increase of pacing rate was found to be dependent on how Ca 2þ loading of the preparation varies with pacing rate (Frampton et al., 1991) . In agreement with Frampton et al (1991) , our data show that the Fig. 5 ). Although future studies should quantitatively assess this descriptive behavior we noted in dog cardiomyocytes, the aim of our study was not to investigate the characteristics of the Sarc. short.-CL relationship in this species. Further explanations for this variable relationship in dog cardiomyocytes could be explained by a difference in (1) species, (2) age of dogs used in this study (age range of our dogs 17-60 months; see Lakatta, 1993; Lim et al., 1999; Schmidt et al., 2000) , and (3) number of cells assessed (eg 766 [our study] versus 34 [Lim et al., 2000] and 43 [Wang et al., 2001] ). Additionally, when the amplitude of the contraction (expressed as shortening) is used to describe the Sarc.short.-CL relation, the results seem to vary significantly (Meyer et al., 1999) . We cannot rule out factors other than those suggested here that might contribute to the variable relationship observed. More importantly, we found that the variable Sarc.short.-CL relationship reported in this study did not impact on inotropic responses on contractility parameters and hysteresis loops.
It is now well accepted that there is a clear need to remove or identify a potential cardiac contractility liability during the drug discovery process. Therefore, in vitro screening (Harmer et al., 2012; Peters et al., 2015; Pointon et al., 2014; Scott et al., 2014; Sirenko et al., 2013b) and in vivo models (Markert et al., 2007; Marks et al., 2012) have been used for the assessment of changes in myocardial contractility during early and late stages of drug discovery, respectively. The primary aim of the in vitro models is hazard detection (ie raise a flag that a drug is active or not) and investigation of structure-activity relationships (SARs) for a broader set of drugs. However, contractility-derived data from these models do not offer mechanistic information and several follow-up secondary pharmacology studies will be required to further explore the potential inotropic liability. Data presented in this study suggest that, in addition to detecting a contractility hazard, the use of different pacing rates may provide an improved ability to detect the inotropes including the atypical profile of omecamtiv mecarbil (further data that may help determining the mechanism underlying this atypical profile are shown in Supplementary Fig. 9 ), illustrate the potential for finger-printing different mechanisms of action (Figs. 2-5 ) that include those involving ion channels, pumps, enzymes, Ca 2þ handling, and contractile proteins, and therefore notably increase the basic usefulness of the contractility assay in early drug discovery. Moreover, current cardiac safety strategies rely on linking secondary pharmacology information, such as potency data at cardiac ion channels and other molecular targets, to the observed inotropic effect. Hence, it would be logical from now on to run the following screening process: (1) assess a drug using the Harmer et al. (2012) myocyte contractility assay, (2) generate an array of secondary pharmacology data for this drug, and (3) run the myocyte contractility assay with different CLs if the secondary pharmacology data suggested a risk. Derived data from this proposed screening approach may better support the identification (ie find out the underlying mechanism that affects cardiomyocyte contractility), mitigation (ie develop a model to screen drugs against this molecular mechanism), and elimination (ie eliminate inotropic liability from a chemical series) of risk. We have made use of the IonOptix system to collect high resolution contractility and intracellular Ca 2þ information from isolated cardiomyocytes, although this system is low-throughput. Thus, the objective in the near future will be to devise a high throughput assay that could come from a plate-based system to simultaneously measure contractility and Ca 2þ transients in paced native cardiomyocytes, or for example, human stem cell-derived cardiomyocytes, and therefore enable the full value of our assay to be realized with routine mechanistic screening for drug discovery program. Data from this study also suggest that the assay was capable of better characterizing the inotropic effects of 10 AZ proprietary drugs from multiple therapeutic classes using the finger-printing C-E curve data , and the hysteresis loops were not determined because of the assay's limited throughput.
Having established that the assay may well be beneficial to assessing effects of drugs on contractility ( Fig. 5 ; Supplementary  Figs . 6-8), a translational validation study using a high throughput plate-based device needs to be conducted with a number of other drugs that have been already tested in multiple follow-up secondary pharmacology studies to fully assess the utility of our finger-printing data in predicting contractility liability. If the predictivity is considered good, it would be logical in the future to run the following screening process: (1) finger-print the mechanistic of a drug and (2) confirm the mechanism of action by generating specific secondary pharmacology data for this drug.
Furthermore, quantitative SAR (QSAR) models of ion channels are currently being applied to correlate structural or property descriptors of drugs with potencies against ion channels (Gavaghan et al., 2007; Hasselgren et al., 2013) . For example as a result of the use of plate-based electrophysiology systems and the development of human ether-a-go-go-related gene (hERG) potassium channel QSAR models, progressively fewer highly potent hERG blockers are being synthesized in drug discovery projects (Hasselgren et al., 2013) . Therefore, it is likely that a contractility QSAR model can be built as a result of the use of a plate-based "finger-printing identification" system with the aim of getting novel drugs with no contractility concern. Moreover, Sarc. shortening-Ca 2þ and left ventricular pressure-volume loops have been used to better understand the electromechanical modulation of cardiomyocyte function (Dulce et al., 2013; Krishna et al., 2013; O'Rourke et al., 1990; Pohlmann et al., 2007; Rota et al., 2005; Soppa et al., 2008; Timolati et al., 2009; ) and ventricular function in response to changes in inotropy (eg Bonow et al., 1983; Piscione et al., 1987; Udelson et al., 1989) , respectively. Although this work is the first example of expanding the Ca 2þ -Sarc. short. loop analysis into the field of cardiac safety science, the volume of testing required to determine how well data generated using the finger-printing identification system translate to expected contractility effects in humans can be overcome with the high throughput system that simultaneously measures contractility and Ca 2þ transient in paced cardiomyocytes. Taken together, our data, future technological advances and finger-printing identification approach may provide an important step change in the assessment of the inotropic potential of new drugs.
In conclusion, our data show that the use of different pacing rates may provide an improved ability to detect the inotropes, illustrate the potential for finger-printing different mechanisms of action and therefore notably contribute toward supporting the discovery and development of safer novel drugs.
SUPPLEMENTARY DATA
Supplementary data are available online at http://toxsci.oxford journals.org.
FUNDING
This work was supported by AstraZeneca.
